OMass Therapeutics Ltd, a 2016 spin-out from the University of Oxford, has raised $310 million in a Series C financing to support development of its lead programme for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. The funding was announced on 15 October.
Both conditions are rare hormone disorders. Congenital adrenal hyperplasia is caused by an enzyme deficiency that impairs cortisol synthesis, while Cushing’s syndrome is characterised by excess cortisol in the body. OMass’s lead product, OMS1620, is a small molecule drug that binds to a receptor on the adrenal glands to normalise hormone levels.
The financing round will enable OMass to advance OMS1620 through Phase 2 in both indications. The molecule is currently in a Phase 1 study in healthy volunteers. Preclinical data disclosed in July 2025 showed that the molecule had the potential to counter surges of the adrenocorticotropic hormone by antagonising the MC2 receptor on the adrenal glands.
The Series C financing was co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings with additional participation from Janus Henderson Investors, SV Health Investors and Jefferson Life Sciences.
It follows a Series B financing of $100 million in May 2022. In a statement, Evan Greif of Bain Capital, said OMass is not only executing against its vision to advance OMS1620, but also building a broader pipeline across endocrinology and immunology.
OMass’s technology is based on the work of Carol Robinson, a professor of chemistry at Oxford. Her laboratory used native mass spectrometry to study proteins in the cell membrane yielding new information on the structure, binding partners and dynamics of proteins. This enabled the identification of small molecules that could potentially modulate membrane proteins associated with disease.
Copyright 2026 Evernow Publishing Ltd